Skip to main content
Assets
Pfizer logo
PFE.NYSE
Pfizer
Health Care · Pharmaceuticals

Global pharmaceutical company developing vaccines and medicines for oncology, inflammation, cardiovascular, and rare diseases including COVID-19 vaccine.

HQ: United StatesListed: United States

Historical AI Opinions

Audit every published iPulse AI forecast batch and immutable historical research document for Pfizer.

Historical AI ConsensusHistorical AI Opinions

Pfizer Inc. (PFE.NYSE) AI OPINIONS & ADVISOR ANALYSIS

Read and compare the 12 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 5 July 2026Deep analysis 5 July 2026

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
Elon Musk AI advisor icon

Elon Musk AI

Gemini 3.1 Pro
The Visionary FrameworkAI Thinker

Model rating

Buy

5-Year Return Est.

+168.4%

Includes 4.35% annual net dividend contribution

1. Investment Thesis — Base Case

Pfizer represents a severely mispriced, highly asymmetrical 'Adaptive Survivor' traversing the trough of a major paradigm shift. The base case sees near-term sluggishness as legacy revenues decay, ultimately overwhelmed by an accelerating R&D engine powered by AI clinical integration.

  • The $24.3 entry point offers massive ; the downside of patent cliffs is already priced in.
  • BIOSECURE guarantees Pfizer's immense internal manufacturing base becomes a asset.
  • will slowly pivot from dividend defense to accretive M&A as pre-revenue biotechs capitulate to high rates.
  • The physics of their pipeline will improve: Seagen combined with automated AI trial matching will compress costs and timeline to market.
  • The implied market cap of $139B is fundamentally disconnected from the of their data moats and manufacturing scale; fair value approaches $250B+ as the AI-pharma integration takes hold.

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.18.0729.7541.4353.1164.79Jul 2021Jan 2024Jul 2026Dec 2028Jul 2031Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in USD.
View chart values
Historical prices and published forecast — published chart values
SeriesDateValue (USD)
Observed price2021-07-0339.7
Observed price2021-07-0839.6
Observed price2021-07-2441.6
Observed price2021-07-2942.8
Observed price2021-08-2049.0
Observed price2021-08-2548.0
Observed price2021-09-1544.5
Observed price2021-09-2144.0
Observed price2021-10-1241.9
Observed price2021-10-1742.4
Observed price2021-11-0849.5
Observed price2021-11-1350.5
Observed price2021-11-2953.6
Observed price2021-12-1053.4
Observed price2021-12-1560.9
Observed price2022-01-1155.8
Observed price2022-01-2252.7
Observed price2022-02-0153.9
Observed price2022-02-2347.9
Observed price2022-02-2847.8
Observed price2022-03-2153.8
Observed price2022-04-1253.0
Observed price2022-04-1750.7
Observed price2022-05-0348.6
Observed price2022-05-1450.9
Observed price2022-05-3053.6
Observed price2022-06-1051.1
Observed price2022-06-1548.6
Observed price2022-07-0652.0
Observed price2022-07-1252.5
Observed price2022-08-0249.7
Observed price2022-08-1349.8
Observed price2022-08-2946.0
Observed price2022-09-0946.8
Observed price2022-09-2544.5
Observed price2022-09-3044.4
Observed price2022-10-1142.1
Observed price2022-10-2746.4
Observed price2022-11-1748.4
Observed price2022-11-2248.8
Observed price2022-12-1451.7
Observed price2022-12-1951.5
Observed price2023-01-1047.8
Observed price2023-01-1545.9
Observed price2023-01-3143.7
Observed price2023-02-1143.3
Observed price2023-02-2740.8
Observed price2023-03-0939.5
Observed price2023-03-3140.7
Observed price2023-04-1041.6
Observed price2023-04-2638.7
Observed price2023-05-0239.0
Observed price2023-05-1836.6
Observed price2023-05-2938.2
Observed price2023-06-1440.0
Observed price2023-06-2437.7
Observed price2023-07-0535.7
Observed price2023-07-2137.0
Observed price2023-08-0135.3
Observed price2023-08-2236.8
Observed price2023-09-0734.3
Observed price2023-09-1234.1
Observed price2023-09-2833.2
Observed price2023-10-0933.2
Observed price2023-10-2530.3
Observed price2023-11-0530.7
Observed price2023-11-1629.5
Observed price2023-12-0228.9
Observed price2023-12-1226.7
Observed price2024-01-0329.7
Observed price2024-01-1928.3
Observed price2024-01-2427.8
Observed price2024-01-2927.2
Observed price2024-03-0126.8
Observed price2024-03-1228.0
Observed price2024-03-1827.7
Observed price2024-04-0826.4
Observed price2024-04-2425.7
Observed price2024-05-0528.0
Observed price2024-05-1028.2
Observed price2024-05-2628.8
Observed price2024-06-0628.8
Observed price2024-06-1627.5
Observed price2024-07-0828.0
Observed price2024-07-2430.0
Observed price2024-07-2931.3
Observed price2024-08-0928.6
Observed price2024-08-3028.5
Observed price2024-09-1529.5
Observed price2024-09-2129.4
Observed price2024-10-0128.7
Observed price2024-10-1729.2
Observed price2024-11-0826.7
Observed price2024-11-1326.1
Observed price2024-11-1825.1
Observed price2024-12-1525.7
Observed price2024-12-3126.6
Observed price2025-01-0626.8
Observed price2025-01-2226.1
Observed price2025-02-0126.3
Observed price2025-02-1225.6
Observed price2025-03-1126.4
Observed price2025-03-2125.9
Observed price2025-03-2725.1
Observed price2025-04-1222.0
Observed price2025-04-2824.0
Observed price2025-05-0922.3
Observed price2025-05-1923.0
Observed price2025-06-1024.3
Observed price2025-06-2024.1
Observed price2025-07-0625.6
Observed price2025-07-1225.4
Observed price2025-08-0223.7
Observed price2025-08-0724.4
Observed price2025-08-1825.3
Observed price2025-09-0824.9
Observed price2025-09-2524.0
Observed price2025-10-0526.4
Observed price2025-10-1624.5
Observed price2025-11-0624.5
Observed price2025-11-1225.9
Observed price2025-11-2825.2
Observed price2025-12-0825.9
Observed price2025-12-2424.9
Observed price2026-01-0425.3
Observed price2026-01-1525.6
Observed price2026-02-0527.0
Observed price2026-02-2727.6
Observed price2026-03-0426.7
Observed price2026-03-2527.0
Observed price2026-03-3127.9
Observed price2026-04-0527.8
Observed price2026-04-2626.8
Observed price2026-05-0226.4
Observed price2026-05-1825.7
Observed price2026-06-0826.1
Observed price2026-06-1925.3
Observed price2026-07-0523.8
Observed price2026-07-1625.1
Observed price2026-07-2624.7
Observed price2026-08-0626.4
Observed price2026-08-1726.9
Observed price2026-09-0229.0
Observed price2026-09-1427.7
Observed price2026-09-1627.5
Observed price2026-09-1827.7
Published advisor forecast2026-07-0224.3
Published advisor forecast2026-10-0223.6
Published advisor forecast2027-01-0224.5
Published advisor forecast2027-04-0225.8
Published advisor forecast2027-07-0227.3
Published advisor forecast2027-10-0226.8
Published advisor forecast2028-01-0228.6
Published advisor forecast2028-04-0230.9
Published advisor forecast2028-07-0232.5
Published advisor forecast2028-10-0233.8
Published advisor forecast2029-01-0235.8
Published advisor forecast2029-04-0236.9
Published advisor forecast2029-07-0235.4
Published advisor forecast2029-10-0237.2
Published advisor forecast2030-01-0240.1
Published advisor forecast2030-04-0242.5
Published advisor forecast2030-07-0244.2
Published advisor forecast2030-10-0245.6
Published advisor forecast2031-01-0247.9
Published advisor forecast2031-04-0249.8
Published advisor forecast2031-07-0252.8

2. Scenarios & Signals

Bull case

The 'Moonshot' scenario unfolds if Pfizer actively aggressively cuts its dividend to fund a massive pivot into AI-native biological capabilities, or if their oncology ADC pipeline delivers pan-tumor efficacy.

  • AI trial automation compresses pipeline timelines by 60%.
  • Pfizer dominates as the central manufacturing and distribution API for all hyperscaler-backed biology breakthroughs.
  • Margins expand violently as R&D efficiency skyrockets, driving the stock toward terminal paradigm-shifter multiples.

Bear case

The '' narrative confirms itself. Bureaucracy stifles , and they fail to integrate AI meaningfully.

  • Patent cliffs arrive faster than pipeline replacements.
  • from policy destroys .
  • The Board defends the dividend to the bitter end, starving the company of R&D capital, ultimately facing a Kodak-style irrelevance as AI-native upstarts bypass them.

Current crowd narrative

The crowd views Pfizer as a post-COVID one-hit wonder suffering a brutal hangover. Wall Street is anchoring on the 7% , treating the stock as a melting ice cube and a dead-money . Sell-side research fixates on the loss of Paxlovid/Comirnaty revenues, imminent patent cliffs, and fears of drug pricing pressure, entirely ignoring the underlying structural value of the data and infrastructure.

Alpha-gap assessment

The crowd misprices the physical bottleneck of modern biology. The market believes AI will disrupt pharma by instantly inventing cures in a server rack. This is a flawed first-principles assumption. AI solves the 'bit' problem of molecule discovery, but the 'atom' problem—clinical validation, FDA navigation, and massive physical manufacturing—remains the true bottleneck. Pfizer's unparalleled global trial infrastructure and exabyte-scale clinical datasets are the mandatory physical API for AI-generated biology. They are not the pioneers of AI, but they are the inescapable for its biological deployment.

Convergence catalyst

The will close when Pfizer announces its first regulatory approval of a major compound discovered and navigated through an AI-augmented pipeline, demonstrating a 3x compression in standard timeline and cost metrics. Expect this validation signal within 18-24 months.

Complete advisor preview locked

Unlock this report and every AI Advisor

Sign in to check your access, or upgrade to the Base plan to read this report and open every advisor.

Sign in to check accessView Base planReturn to latest AI Consensus